{"1XT.F": {"short_name": "XINTELA AB", "long_name": "Xintela AB (publ)", "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "2I9.F": {"short_name": "KAROLINSKA DEVELOP.AB", "long_name": "Karolinska Development AB (publ)", "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "3EE.F": {"short_name": "KANCERA AB", "long_name": "Kancera AB (publ)", "summary": "Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. It develops drugs for the treatment of inflammation and cancer. The company's drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB3 inhibitors for reducing cancer's energy supply and inhibiting DNA repair; HDAC6 for the treatment of nerve inflammation and pain; and KAND567 and KAND145 that block the receptor for fractalkine and specific parts of the immune system, as well as for the treatment of heart injury after myocardial infarction. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "4CX.F": {"short_name": "CYXONE AB  SK-,75", "long_name": "Cyxone AB (publ)", "summary": "Cyxone AB (publ), a clinical biotech company, develops immunomodulatory drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "4K4.F": {"short_name": "STAYBLE THERAPEUTICS AB", "long_name": "Stayble Therapeutics AB (publ)", "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "52X.F": {"short_name": "MAGLE CHEMOSWED HOLDING", "long_name": "Magle Chemoswed Holding AB (publ)", "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in Malm\u00c3\u00b6, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "5GV.F": {"short_name": "GENOVIS AB  SE-,40", "long_name": "Genovis AB (publ.)", "summary": "Genovis AB (publ.) develops, produces, and sells tools for developing drugs for customers in the medical device and pharmaceutical industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1 at one specific site above the hinge and generating intact Fab and Fc fragments; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for producing a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues, including arginine linked to proline; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company was founded in 1999 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "5IU.F": {"short_name": "ISOFOL MEDICAL AB", "long_name": "Isofol Medical AB (publ)", "summary": "Isofol Medical AB (publ), a biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops Arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was founded in 2008 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "5J9.F": {"short_name": "FLUICELL AB", "long_name": "Fluicell AB (publ)", "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "5LU.F": {"short_name": "SIMRIS ALG AB  B", "long_name": "Simris Alg AB (publ)", "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in Hammenh\u00c3\u00b6g, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Hammenh\u00c3\u00b6g"}, "65G.F": {"short_name": "NEXTCELL PHARMA AB", "long_name": "NextCell Pharma AB", "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Huddinge"}, "6XP.SG": {"short_name": "XSpray Pharma AB Namn-Aktier o.", "long_name": "Xspray Pharma AB (publ)", "summary": "Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was founded in 2003 and is based in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "6Y4.F": {"short_name": "VICORE PHARMA HOLDING AB", "long_name": "Vicore Pharma Holding AB (publ)", "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; and license agreement with Nanologica AB (publ). The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "78D.F": {"short_name": "ALZINOVA AB", "long_name": "Alzinova AB", "summary": "Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer's disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric A\u00c3\u009f. The company was founded in 2011 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "7AL.F": {"short_name": "ALLIGATOR BIOSC. AB O.N.", "long_name": "Alligator Bioscience AB (publ)", "summary": "Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific antibody formats for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB (CD137) in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody to treat solid tumors and hematologic cancers. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "7CA.F": {"short_name": "CAMURUS AB", "long_name": "Camurus AB (publ)", "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, North America, and Asia. It offers Buvidal, an injection solution for the treatment of opioid dependence; and episil oral liquid is a medical device for the treatment of inflammatory and painful conditions in the oral cavity. The company's products pipeline also includes CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment acromegaly and in phase II clinical trials for the treatment neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension. In addition, it develops CAM2032 for the treatment of prostate cancer; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4072 that is in phase III clinical trials for the treatment of rare genetic obesity disorders; and CAM4083, a pre-clinical stage product for treatment of myasthenia gravis, immune-mediated necrotizing myopathy, and other tissue disorders, as well as CAM2047, CAM2048, and CAM2058 for the treatment of chemotherapy induced nausea and vomiting, postoperative pain, and postoperative nausea and vomiting. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "7V3.F": {"short_name": "CANTARGIA AB", "long_name": "Cantargia AB (publ)", "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "99B.F": {"short_name": "QUIAPEG PHARMAC.H.SK-1,20", "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)", "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "9IB.SG": {"short_name": "Infant Bacterial Therapeutics N", "long_name": "Infant Bacterial Therapeutics AB (publ)", "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "A6X.F": {"short_name": "AXICHEM AB A", "long_name": "aXichem AB", "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "ACE.ST": {"short_name": "Ascelia Pharma AB", "long_name": "Ascelia Pharma AB (publ)", "summary": "Ascelia Pharma AB (publ) operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase III for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase II for the treatment of gastric cancer. The company was founded in 2000 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "ACOU.ST": {"short_name": "AcouSort AB", "long_name": "AcouSort AB (publ)", "summary": "AcouSort AB (publ), a biotech company, develops proprietary bioanalytical and clinical applications based on acoustophoresis. It offers AcouTrap, a tabletop research platform for acoustic trapping; AcouPlasma, a blood-plasma separation module that enables analysis of blood plasma from whole blood samples; and AcouWash, a stand-alone table top research tool, which applies acoustic forces to focus cells. The company was founded in 2010 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "ALZ.ST": {"short_name": "Alzinova AB", "long_name": "Alzinova AB", "summary": "Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer's disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric A\u00c3\u009f. The company was founded in 2011 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "ANNX.ST": {"short_name": "Annexin Pharmaceuticals AB", "long_name": "Annexin Pharmaceuticals AB (publ)", "summary": "Annexin Pharmaceuticals AB (publ), a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ASAP.ST": {"short_name": "Asarina Pharma AB", "long_name": "Asarina Pharma AB (publ)", "summary": "Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "ATORX.ST": {"short_name": "Alligator Bioscience AB", "long_name": "Alligator Bioscience AB (publ)", "summary": "Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific antibody formats for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB (CD137) in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody to treat solid tumors and hematologic cancers. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "AXIC-A.ST": {"short_name": "aXichem AB ser. A", "long_name": "aXichem AB", "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "B9A.F": {"short_name": "BIOARCTIC AB B", "long_name": "BioArctic AB (publ)", "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "BINV.ST": {"short_name": "BioInvent International AB", "long_name": "BioInvent International AB (publ)", "summary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "BIOA-B.ST": {"short_name": "BioArctic AB ser. B", "long_name": "BioArctic AB (publ)", "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "BIOVIC-B.ST": {"short_name": "Biovica International AB ser. B", "long_name": "Biovica International AB (publ)", "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "BIOWKS.ST": {"short_name": "Bio-Works Technologies AB", "long_name": "Bio-Works Technologies AB (publ)", "summary": "Bio-Works Technologies AB (publ) researches, develops, manufactures, and supplies agarose based resins used to separate proteins and other biomolecules. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography (IMAC) resins; ion exchange resins; OptioBio glass columns; and size exclusion chromatography (SEC) resins. The company's products are used in antibody, His-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines purification process. Bio-Works Technologies AB (publ) founded in 2006 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "BIX0.F": {"short_name": "BIOINVENT INTERN.  SK 2", "long_name": "BioInvent International AB (publ)", "summary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "BTPC.F": {"short_name": "ACTIVE BIOTECH  SK 10", "long_name": "Active Biotech AB (publ)", "summary": "Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops pharmaceuticals for the treatment of cancer and inflammatory diseases in Sweden. The company is involved in developing Naptumomab, an immunotherapy that is in Phase Ib/II clinical trial for treatment of solid tumors; and Tasquinimod, an immunomodulator to treat multiple myeloma. It is also developing Laquinimod, an immunomodulator or the treatment of eye disorders; wet age-related macular degeneration and uveitis; and Crohn's disease, an inflammatory bowels disease. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "CAMX.ST": {"short_name": "Camurus AB", "long_name": "Camurus AB (publ)", "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, North America, and Asia. It offers Buvidal, an injection solution for the treatment of opioid dependence; and episil oral liquid is a medical device for the treatment of inflammatory and painful conditions in the oral cavity. The company's products pipeline also includes CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment acromegaly and in phase II clinical trials for the treatment neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension. In addition, it develops CAM2032 for the treatment of prostate cancer; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4072 that is in phase III clinical trials for the treatment of rare genetic obesity disorders; and CAM4083, a pre-clinical stage product for treatment of myasthenia gravis, immune-mediated necrotizing myopathy, and other tissue disorders, as well as CAM2047, CAM2048, and CAM2058 for the treatment of chemotherapy induced nausea and vomiting, postoperative pain, and postoperative nausea and vomiting. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CANTA.ST": {"short_name": "Cantargia AB", "long_name": "Cantargia AB (publ)", "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CLBIO.ST": {"short_name": "Corline Biomedical AB", "long_name": "Corline Biomedical AB", "summary": "Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "CMOTEC-B.ST": {"short_name": "Scandinavian ChemoTech AB B", "long_name": "Scandinavian ChemoTech AB (publ)", "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CYXO.ST": {"short_name": "Cyxone AB", "long_name": "Cyxone AB (publ)", "summary": "Cyxone AB (publ), a clinical biotech company, develops immunomodulatory drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "DMN.F": {"short_name": "DIAMYD MEDICAL B", "long_name": "Diamyd Medical AB (publ)", "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "DMYD-B.ST": {"short_name": "Diamyd Medical AB ser. B", "long_name": "Diamyd Medical AB (publ)", "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "EGTX.ST": {"short_name": "Egetis Therapeutics AB", "long_name": "Egetis Therapeutics AB (publ)", "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "FLUI.ST": {"short_name": "Fluicell AB", "long_name": "Fluicell AB (publ)", "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "GENO.ST": {"short_name": "Genovis AB", "long_name": "Genovis AB (publ.)", "summary": "Genovis AB (publ.) develops, produces, and sells tools for developing drugs for customers in the medical device and pharmaceutical industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1 at one specific site above the hinge and generating intact Fab and Fc fragments; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for producing a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues, including arginine linked to proline; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company was founded in 1999 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "HNSA.ST": {"short_name": "Hansa Biopharma AB", "long_name": "Hansa Biopharma AB (publ)", "summary": "Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barr\u00c3\u00a9 syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Limited for Heparin Binding Protein (HBP)-assay, a method that predicts severe sepsis in emergency clinics. Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "IBT-B.ST": {"short_name": "Infant Bacterial Therapeutics A", "long_name": "Infant Bacterial Therapeutics AB (publ)", "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "IDOGEN.ST": {"short_name": "Idogen AB", "long_name": "Idogen AB (publ)", "summary": "Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection; and IDO AID for severe and rare autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "IRLAB-A.ST": {"short_name": "IRLAB Therapeutics AB ser. A", "long_name": "IRLAB Therapeutics AB (publ)", "summary": "IRLAB Therapeutics AB (publ), a research and development company, develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa clinical trial for the treatment of dyskinesia; IRL752 that has completed Phase IIa clinical trial to treat postural dysfunction; and IRL942 and 1009, a research program for the treatment of neurodegenerative disorders and ageing. It also develops P001, a research project for neurodegenerative disorders and aging; P003, a research project aiming at developing drugs that can substitute levodopa as the treatment of Parkinson's disease; and IRL448/IRL555, a follow\u00c2\u0096up to Parkinson's disease program. The company is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "ISOFOL.ST": {"short_name": "Isofol Medical AB", "long_name": "Isofol Medical AB (publ)", "summary": "Isofol Medical AB (publ), a biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops Arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was founded in 2008 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "ISR.ST": {"short_name": "ISR Immune System Regulation Ho", "long_name": "ISR Immune System Regulation Holding AB (publ)", "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ITECH.ST": {"short_name": "I-Tech AB", "long_name": "I-Tech AB", "summary": "I-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. It serves marine coatings manufacturers. The company was founded in 2000 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "IVACC.ST": {"short_name": "Intervacc AB", "long_name": "Intervacc AB (publ)", "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in H\u00c3\u00a4gersten, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "H\u00c3\u00a4gersten"}, "KAN.ST": {"short_name": "Kancera AB", "long_name": "Kancera AB (publ)", "summary": "Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. It develops drugs for the treatment of inflammation and cancer. The company's drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB3 inhibitors for reducing cancer's energy supply and inhibiting DNA repair; HDAC6 for the treatment of nerve inflammation and pain; and KAND567 and KAND145 that block the receptor for fractalkine and specific parts of the immune system, as well as for the treatment of heart injury after myocardial infarction. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "KDEV.ST": {"short_name": "Karolinska Development AB ser.B", "long_name": "Karolinska Development AB (publ)", "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "LIDDS.ST": {"short_name": "LIDDS AB", "long_name": "LIDDS AB (publ)", "summary": "LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an antibody-based immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. The company is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "MAGLE.ST": {"short_name": "Magle Chemoswed Holding AB", "long_name": "Magle Chemoswed Holding AB (publ)", "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in Malm\u00c3\u00b6, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "MVIR-B.ST": {"short_name": "Medivir AB ser. B", "long_name": "Medivir AB (publ)", "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform and SciLifeLab for the discovery of antivirals for SARS CoV-2. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Huddinge"}, "MVR.F": {"short_name": "MEDIVIR AB B  SK 10", "long_name": "Medivir AB (publ)", "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform and SciLifeLab for the discovery of antivirals for SARS CoV-2. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Huddinge"}, "NXTCL.ST": {"short_name": "NextCell Pharma AB", "long_name": "NextCell Pharma AB", "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Huddinge"}, "ONCO.ST": {"short_name": "Oncopeptides AB", "long_name": "Oncopeptides AB (publ)", "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "OND.F": {"short_name": "ONCOPEPTIDES AB O.N.", "long_name": "Oncopeptides AB (publ)", "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "ONPPF": {"short_name": "ONCOPEPTIDES AB", "long_name": "Oncopeptides AB (publ)", "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "P0F.F": {"short_name": "EGETIS THERAPEUTICS AB", "long_name": "Egetis Therapeutics AB (publ)", "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "P0F.SG": {"short_name": "EGETIS THERAPEUTICS AB", "long_name": "Egetis Therapeutics AB (publ)", "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "PROMO.ST": {"short_name": "Promore Pharma AB", "long_name": "Promore Pharma AB (publ)", "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 for the prevention of post-surgical adhesions and scars, as well as for tendon repair surgery in the hand; and LL-37 that is in Phase IIb clinical studies for treating patients with venous leg ulcers. The company is also developing drugs for the prevention of dermal scars and treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "QUIA.ST": {"short_name": "QuiaPEG Pharmaceuticals Holding", "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)", "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "RECI-B.ST": {"short_name": "Recipharm AB ser. B", "long_name": "Recipharm AB (publ)", "summary": "Recipharm AB (publ) provides contract development and manufacturing solutions to the pharmaceutical industry in Sweden, Italy, France, India, Spain, Portugal, Germany, and internationally. It operates through three segments: Manufacturing Steriles & Inhalation, Manufacturing Solids and Others, and Development and Technology. The company manufactures liquid vials and ampoules, lyophilisates, and blow-fill-seal products and inhalation; and tablets, capsules, semi-solids, and non-sterile liquids on behalf of pharmaceutical companies. It also provides supplementary services, such as regulatory, supply chain, active life cycle management, and stability studies and analytical method development services, as well as gateway release and testing services. In addition, the company offers pharmaceutical development services based on various technologies, such as drug substance, drug product, and clinical services to pharmaceutical companies in the drug development phase for new pharmaceuticals; and access to a range of proprietary technologies and intellectual property. Further, it supplies medical devices and veterinary products; and solid, semi-solid, liquid, injectable, and ophthalmic products, as well as serialization services. The company serves various pharma, and research and development companies. The company was founded in 1995 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "SIMRIS-B.ST": {"short_name": "Simris Alg AB ser. B", "long_name": "Simris Alg AB (publ)", "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in Hammenh\u00c3\u00b6g, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Hammenh\u00c3\u00b6g"}, "STABL.ST": {"short_name": "Stayble Therapeutics AB", "long_name": "Stayble Therapeutics AB (publ)", "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "VICO.ST": {"short_name": "Vicore Pharma Holding AB", "long_name": "Vicore Pharma Holding AB (publ)", "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; and license agreement with Nanologica AB (publ). The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "XBRANE.ST": {"short_name": "Xbrane Biopharma AB", "long_name": "Xbrane Biopharma AB (publ)", "summary": "Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and neck, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars and additional biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "XINT.ST": {"short_name": "Xintela AB", "long_name": "Xintela AB (publ)", "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "XSPRAY.ST": {"short_name": "Xspray Pharma AB", "long_name": "Xspray Pharma AB (publ)", "summary": "Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was founded in 2003 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}}